Apolipoprotein A-I (Apolipoprotein A1)

The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE.

Also Known As:

Networked: 2703 relevant articles (107 outcomes, 385 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Navab, Mohamad: 35 articles (12/2015 - 01/2002)
2.	Fogelman, Alan M: 32 articles (12/2015 - 01/2002)
3.	Anantharamaiah, G M: 29 articles (08/2015 - 03/2001)
4.	Rye, Kerry-Anne: 24 articles (11/2015 - 06/2004)
5.	Rader, Daniel J: 23 articles (10/2015 - 05/2002)
6.	Reddy, Srinivasa T: 23 articles (08/2015 - 09/2003)
7.	Remaley, Alan T: 18 articles (05/2015 - 04/2003)
8.	Kastelein, John J P: 17 articles (07/2015 - 10/2004)
9.	Schaefer, Ernst J: 16 articles (05/2015 - 10/2002)
10.	Asztalos, Bela F: 16 articles (05/2015 - 10/2002)

Related Diseases

1.	Atherosclerosis 03/18/2008 - "Acute plaque regression observed after short-term apoA-I(Milano) administration was associated with a significant reduction in suspected makers of plaque vulnerability in an experimental model of atherosclerosis." 06/03/1985 - "One molecular variant, Apo AI-Milano, while leading to a significant reduction of HDL, does not seem to be associated with clinical atherosclerosis, but rather with a protection from the disease. " 05/01/1992 - "Conclusively, apo A1 is effective in preventing the development of experimental atherosclerosis. " 08/18/2003 - "However, overexpression of apolipoprotein A-I in animals has been shown to reduce progression and even induce regression of atherosclerosis, indicating that apolipoprotein A-I is directly protective against atherosclerosis. " 02/01/2014 - "Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background."
2.	Inflammation 02/01/2010 - "We investigated whether the 5A peptide shares other beneficial features of apoA-I, such as protection against inflammation and oxidation. " 02/01/2011 - "Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation." 09/01/2013 - "Even more provocative are recent studies showing that apoA-I, the principle protein component of HDL modulates cellular inflammation and oxidation. " 01/01/2011 - "In this study, we hypothesized that an apoA-I mimetic peptide might be effective at inhibiting asthmatic airway inflammation. " 11/01/2015 - "ApoA-I restores the neovascularization capacity of the lymphatic system during TNF-mediated inflammation. "
3.	Coronary Artery Disease (Coronary Atherosclerosis) 12/01/2013 - "The present study was designed to investigate whether the three-apolipoprotein (AI, B, E) gene polymorphisms were related to alter their plasma protein levels and hence associated to coronary artery disease (CAD). " 09/30/2008 - "These findings may be relevant to the study of a novel function of karyopherin beta3 and coronary artery diseases associated with apo A-I." 12/01/1998 - "This study was designed to examine the relationship between polymorphism at the Apo A1 gene and the risk of early coronary artery disease. " 10/01/1991 - "This study describes a variant of familial apoA-I deficiency associated with a moderate risk for premature coronary artery disease. " 01/01/1991 - "Coronary artery disease and apolipoprotein A-I/C-III gene polymorphism: a study of Saudi Arabians."
4.	Cardiovascular Diseases (Cardiovascular Disease) 10/01/2013 - "In this study, we investigated whether MPO can oxidise HDL and determined MPO-specific oxidative signature by apoA-1 by peptide mapping in RA subjects with and without known cardiovascular disease (CVD). " 02/01/2015 - "N-Glycosylation of apolipoprotein A1 in cardiovascular diseases." 01/01/2015 - "The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?" 01/01/2013 - "These results show that HDL-apoA-I exchange is a clinically relevant measure of HDL function pertinent to cardiovascular disease. " 02/24/2012 - "These observations may have implications for treating cardiovascular disease, because recombinant apoA-I is under investigation as a therapeutic agent and mutant forms of apoA-I that resist oxidation might be more cardioprotective than the native form."
5.	Vascular Diseases (Vascular Disease) 05/27/2011 - "Our results suggest that cleavage of lipid-free apoA-I by MMP-14 may contribute to reduced HDL formation, and this may be occurring during the development of various vascular diseases as lipid metabolism is disrupted." 10/01/2010 - "The results demonstrated accelerated oxidative damage to plasma ApoA-1, thus offering a potential mechanism underlying the impact of poor glycemic control in type 1 diabetic patients that affects a patient's risk for vascular disease." 03/27/2001 - "Despite very low plasma levels of HDL, carriers of the apolipoprotein AI Arg173 --> Cys mutation apoAI(Milano) (AIM) have no apparent increase in risk for atherosclerotic vascular disease. " 05/17/2002 - "Apolipoprotein A-I(Milano) (AIM), a natural variant of human apolipoprotein A-I, confers to carriers a significant protection against vascular disease. " 04/01/2000 - "To measure the blood apolipoprotein A-1 and apolipoprotein B in the fetal circulation in normal pregnancy and in pregnancy with evidence of vascular disease in the fetal umbilical placental circulation defined in the antenatal period by Doppler ultrasound study. "

Related Drugs and Biologics

1.	Apolipoprotein A-I (Apolipoprotein A1)
2.	Lipoproteins (Lipoprotein)
3.	Cholesterol
4.	HDL Cholesterol
5.	Apolipoproteins
6.	Apolipoproteins B (ApoB)
7.	LDL Cholesterol
8.	Triglycerides (Triacylglycerol)
9.	LDL Receptors (LDL Receptor)
10.	Apoproteins

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Ligation
3.	Diet Therapy (Therapy, Diet)
4.	Renal Dialysis (Hemodialysis)
5.	Drug Therapy (Chemotherapy)